Patients may be paying for interventions that have no proven value
In the quiet desperation of fertility clinics around the world, hope has long been sold alongside science — sometimes indistinguishably. A sweeping review published in the Lancet now draws a firm line between the two, finding that most supplementary IVF treatments marketed to improve conception rates lack the clinical evidence to justify their use. The findings invite a reckoning with how medicine behaves when commercial incentive meets human longing, and whether the systems meant to protect patients are keeping pace.
- A landmark Lancet review has exposed a widespread gap between how IVF add-on treatments are marketed and what clinical evidence actually supports.
- Fertility clinics globally — including prominently in Australia — routinely offer patients a menu of optional procedures that have never been rigorously proven to work.
- Patients already stretched thin emotionally and financially are absorbing the cost of these unproven treatments, sometimes at the expense of pursuing care that does have evidence behind it.
- The competitive clinic landscape creates a troubling incentive structure where offering more options, proven or not, functions as a marketing advantage over patient welfare.
- Regulators and professional bodies are now expected to respond, with pressure mounting to require evidence standards before optional treatments can be marketed to vulnerable patients.
A major review published in the Lancet has concluded that most supplementary treatments offered by fertility clinics to improve IVF outcomes are not supported by rigorous scientific evidence. Examining a broad range of add-on services — from specialized embryo selection to various laboratory procedures — the analysis found that the majority either show no measurable benefit or have never been properly studied at all.
These treatments are a fixture of fertility care worldwide. In Australia especially, patients undergoing IVF are routinely presented with optional services framed as ways to improve their odds of conception. The marketing is often persuasive, and the audience is uniquely susceptible: people already emotionally and financially committed to having a child, for whom the cost of inaction feels higher than the cost of trying anything.
The financial toll is real. IVF is already expensive, and add-ons accumulate quickly across multiple cycles. For many patients, the decision to pursue these extras is less about confidence in their effectiveness than about fear — a willingness to spend more in hopes that something might tip the odds, even without a solid evidence base to stand on.
What the Lancet review makes plain is that the fertility medicine field has allowed a significant drift between what is offered and what is proven. Some add-ons have been studied and found ineffective; others have barely been studied at all, yet are presented to patients as established options. The result is a system where commercial incentives and patient vulnerability reinforce each other in ways that may actively work against patients' interests.
The findings are expected to draw regulatory attention and pressure professional bodies to tighten standards around how optional treatments are marketed. For patients navigating fertility care now, the review carries a pointed message: ask whether any add-on has been rigorously tested, and treat clinic marketing with healthy skepticism.
A comprehensive review published in the Lancet has found that most supplementary treatments marketed to improve IVF success rates lack scientific evidence to support their use. The analysis examined a range of add-on services that fertility clinics routinely offer to patients—procedures and treatments positioned as ways to boost the odds of conception—and concluded that the vast majority either show no measurable benefit or remain unproven by rigorous clinical study.
These add-on treatments are ubiquitous in fertility clinics worldwide. In Australia, where the practice is particularly common, patients are regularly offered a menu of optional services alongside their standard IVF cycles. The treatments range from specialized embryo selection techniques to various laboratory procedures, each typically presented to patients as a way to improve their chances of success. Clinics market these services aggressively, often to people already emotionally and financially invested in conception, creating a vulnerable dynamic in which patients may feel compelled to pursue every available option.
The financial burden falls directly on patients. IVF itself is expensive, and these add-ons represent additional costs that accumulate quickly. A patient pursuing multiple cycles with various supplementary treatments can face substantial out-of-pocket expenses. For many, the decision to add these services reflects not confidence in their efficacy but rather desperation—a willingness to spend more money in hopes of improving outcomes, even when the evidence base is thin.
What the Lancet review reveals is a significant gap between marketing and evidence. Most of these treatments have not been subjected to the kind of rigorous clinical trials that would establish whether they actually work. Some have been studied and found to have no effect. Others remain largely unstudied, yet are sold to patients as if their benefit were established. This creates a troubling situation in which patients may be paying for interventions that have no proven value, potentially delaying their access to treatments that do have evidence behind them.
The implications extend beyond individual patient finances. The widespread adoption of unproven add-ons raises questions about how fertility medicine is regulated and marketed. Clinics operate in a competitive landscape where offering more options—even unproven ones—can be a marketing advantage. Patients, desperate and informed by clinic messaging, may feel they would be remiss not to pursue every available avenue. The result is a system in which commercial incentives and patient vulnerability align in ways that may not serve patients' actual interests.
The Lancet findings are likely to prompt scrutiny from regulators and professional bodies. Fertility medicine has long occupied a space where innovation and evidence-based practice sometimes diverge, and where the emotional stakes make patients particularly susceptible to hope-based marketing. This review provides a clear signal that the field needs to tighten the connection between what is offered and what is proven. For patients currently navigating fertility treatment, the message is more cautious: before accepting an add-on treatment, ask whether it has been rigorously tested, and be skeptical of claims that rest on marketing rather than evidence.
Citas Notables
Most complementary treatments for in vitro fertilization lack sufficient evidence that they improve fertility— Lancet review findings
La Conversación del Hearth Otra perspectiva de la historia
Why do fertility clinics keep selling treatments that don't work?
Because they can. Patients are desperate, clinics are competitive, and there's little enforcement. Once a treatment enters the market, it's hard to dislodge it, even if studies later show it's useless.
But don't patients ask for evidence?
Some do. But most are exhausted, emotionally wrung out, and willing to try anything. When a clinic says an add-on might help, the patient hears possibility, not probability. The asymmetry of information is huge.
What's the actual cost to a patient?
It varies, but add-ons can run hundreds to thousands of dollars per cycle. For someone doing multiple cycles, it compounds. That money could go toward more cycles with proven treatments, or toward adoption, or toward accepting childlessness. Instead it vanishes into unproven procedures.
Is this unique to fertility medicine?
No, but it's worse here. Fertility patients are uniquely vulnerable—they've often spent years trying to conceive, they're running against biological clocks, and they're making decisions under emotional duress. It's a perfect storm for exploitation.
What changes after this Lancet review?
Ideally, regulators step in. Clinics are forced to disclose evidence levels. Marketing becomes more honest. But that requires political will, and fertility medicine has always been a bit of a Wild West.